Skip to content Skip to footer
Subscribe Now
New Drug Designations - December 2023
INSIGHTS+

New Drug Designations – December 2023

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EC, and China’s NMPA. This month’s report includes 6 biological drugs, 10 small molecules, 5 cell and gene therapies, 1 recombinant fusion protein, 1 peptide and 2 devices   Neurocrine Biosciences’ Crinecerfont, focused on the treatment of Congenital Adrenal Hyperplasia…
January 25, 2024

Read more

e-Brain OncoVision Connecting the Dots in Cancer Care
EVENTS

e-Brain OncoVision: Connecting the Dots in Cancer Care

Gear up for the most awaited metaverse-based global event!  Don’t miss out on this enlightening conference focussed on Oncology domains by Ingenious E-Brain.  The virtual event “e-Brain OncoVision: Connecting the Dots in Cancer Care” is scheduled for February 15th (9:00AM EST) to February 16th, 2024 (5:30PM EST)  Featuring renowned speakers from leading biopharma companies & organizations, the…
January 18, 2024

Read more

Exclusive_Noelle Bush_2024
EXCLUSIVE

Noelle Bush in an Enlightening Interview with PharmaShots Shares Insights from the It Takes 2 Awareness Program

Shots:  Exemplifying awareness campaign at its best with a hint of contemporary music, “It takes 2” by Boehringer Ingelheim and Eli Lilly is a noble initiative aimed at integrating UACR testing with eGFR for better screening of CKD  Noelle Bush, in an engaging conversation with PharmaShots, cites the growing incidences of CKD in the US.…
January 15, 2024

Read more

Post Collaboration Laura Acosta and Himanshu Sehgal in a Candid Conversation
EVENTS

Post Collaboration: Laura Acosta and Himanshu Sehgal in a Candid Conversation

In pursuit of achieving data-driven excellence, PharmaShots came across Newstex. Soon, as a part of a collaboration PharmaShots and Newstex embarked on a journey to delivering high-quality and unerring content. Himanshu Sehgal, Director at PharmaShots, in a candid conversation with Newstex’s Head of Publisher Solutions, Laura Acosta. While sharing the origin story of PharmaShots, Himanshu…
January 11, 2024

Read more

Disease of the Month - Glioblastoma
INSIGHTS+

Disease of the Month – Glioblastoma

Shots:  The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved  For the January edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Glioblastoma, the most…
January 11, 2024

Read more

Announcements

PharmaShots Announces New Content Partnership with Newstex 

PharmaShots is pleased to announce that we have entered into a new content partnership with Newstex, expanding the reach and impact of our insights across global professional and academic audiences.  This collaboration strengthens our mission to deliver high-quality, timely, and actionable biopharma and healthcare intelligence. By integrating PharmaShots’ curated industry updates into Newstex’s premium content distribution network, we aim to support researchers, analysts, students,…
January 11, 2024

Read more

VIEWPOINTS_Michael Moran1_Julie Blaedel2_2024
VIEWPOINTS

Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots

Shots:    Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL   Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with…
January 10, 2024

Read more

Load more